August 15, 2016


The Gabrail Cancer Center currently has many Clinical Trial opportunities . For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or email

An open label Phase Ia/b dose escalation followed by dose expansion safety and tolerability trial of CAP-100, a humanized C-C-chemokine receptor 7 antibody, administered as monotherapy in subjects with r/r chronic lymphocytic leukemia.

Delta Fly D18-11141: Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle as Monotherapy or in Combination inTreatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy

A phase IB/II study of APG-2575 as a single agent or in combination with other therapeutics agents in patients with relapsed and/or refactory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (SACRED)

A phase 1B study of the pharmacokinetics, safety and efficacy of orally administered HQP1351 in subjects with refactory Chronic Myeloid Leukemia (CML)

A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dociparstat sodium in combination with standard chemotherapy for the treatment of newly-diagnosed acute myeloid leukemia

A Phase Ib/II Study of APG-2575 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS)

Return to Clinical Trials at GCC